Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

In Vitro and in Vivo Pharmacological Characterization of BIIL 284, a Novel and Potent Leukotriene B4 Receptor Antagonist

F. W. Birke, C. J. Meade, R. Anderskewitz, G. A. Speck and H.-M. Jennewein
Journal of Pharmacology and Experimental Therapeutics April 2001, 297 (1) 458-466;
F. W. Birke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. J. Meade
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Anderskewitz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. A. Speck
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H.-M. Jennewein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

BIIL 284 is a new LTB4 receptor antagonist. It is a prodrug and has negligible binding to the LTB4 receptor. However, ubiquitous esterases metabolize BIIL 284 to the active metabolites BIIL 260 and BIIL 315, the glucuronidated form of BIIL 260. Both metabolites have high affinity to the LTB4 receptor on isolated human neutrophil cell membranes with Ki values of 1.7 and 1.9 nM, respectively. On vital human neutrophilic granulocytesKi was around 1 nM. BIIL 260 and BIIL 315 interact with the LTB4 receptor in a saturable, reversible, and competitive manner. BIIL 260 and its glucuronide BIIL 315 also potently inhibited LTB4-induced intracellular Ca2+ release in human neutrophils (IC50 values of 0.82 and 0.75 nM, respectively) as measured with Fura-2. High efficacy of BIIL 284 has been demonstrated in various in vivo models. BIIL 284 inhibited LTB4-induced mouse ear inflammation with ED50 = 0.008 mg/kg p.o., LTB4-induced transdermal chemotaxis in guinea pigs with ED50 = 0.03 mg/kg p.o., LTB4-induced neutropenia in various species (monkey: ED50 = 0.004 mg/kg p.o.), and LTB4-induced Mac1-expression in monkeys (ED50 = 0.05 mg/kg p.o. in Tylose). Full blockade of LTB4 receptors over 24 h was achieved by 0.3 mg/kg BIIL 284 after single oral dose as measured by LTB4-induced neutropenia or Mac1-expression in the monkey model. BIIL 284 is an unusually potent and long-acting orally active LTB4antagonist, and is therefore under clinical development as a novel anti-inflammatory principle.

Footnotes

  • Send reprint requests to: Dr. F. Birke, Abteilung Atemwegsforschung, Boehringer Ingelheim Pharma, KG D-55216 Ingelheim am Rhein, Germany. E-mail:Birke{at}ing.boehringer-ingelheim.com

  • Abbreviations:
    LTB4
    leukotriene B4
    PMNL
    polymorphonuclear leukocyte
    BIIL 284 BS
    carbamic acid, [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenoxy]methyl]phenyl]methoxy]phenyl]iminomethyl]-, ethyl ester
    LY 293111
    benzoic acid, 2-[3-[3-[(5-ethyl-4′-fluoro-2-hydroxy[1,1′-biphenyl]-4yl)oxy]propoxy]-2-propylphenoxy]-, monosodium
    CGS 25019 C
    benzamide, 4-[[5-[4-(aminoiminomethyl)phenoxy]pentyl]oxy]-3-methoxy-N,N-bis(1methylethyl)-, sulfate
    BIIL 260 CL
    benzenecarboximidamide, [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenoxy]methyl]phenyl]methoxy]-, monohydrochloride
    BIIL 315 ZW
    β-d-glucopyranosiduronic acid, 4-[1-[4-[[3-[[4-(aminoiminomethyl)phenoxy]methyl]phenyl]methoxy]phenyl]-1-methylethyl]phenyl
    BSA
    bovine serum albumin
    PBS
    phosphate-buffered saline
    FITC
    fluorescein isothiocyanate
    • Received November 15, 2000.
    • Accepted January 2, 2001.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 297 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 297, Issue 1
1 Apr 2001
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro and in Vivo Pharmacological Characterization of BIIL 284, a Novel and Potent Leukotriene B4 Receptor Antagonist
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

In Vitro and in Vivo Pharmacological Characterization of BIIL 284, a Novel and Potent Leukotriene B4 Receptor Antagonist

F. W. Birke, C. J. Meade, R. Anderskewitz, G. A. Speck and H.-M. Jennewein
Journal of Pharmacology and Experimental Therapeutics April 1, 2001, 297 (1) 458-466;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

In Vitro and in Vivo Pharmacological Characterization of BIIL 284, a Novel and Potent Leukotriene B4 Receptor Antagonist

F. W. Birke, C. J. Meade, R. Anderskewitz, G. A. Speck and H.-M. Jennewein
Journal of Pharmacology and Experimental Therapeutics April 1, 2001, 297 (1) 458-466;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mirabegron Effects in Human Detrusor Tissues
  • Resveratrol Attenuates HFD-Induced Hepatic Lipotoxicity
  • Ligustrazine attenuates liver fibrosis
Show more Gastrointestinal, Hepatic, Pulmonary, and Renal

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics